Section 3: Advanced AS Communication Strategies (Faculty)
Concepts regarding one on one communication in stewardship skills were covered in the CORE Curriculum, this section focuses on more advanced communication skills that are needed in stewardship at a higher level. The main goal in Section 3, is to build upon how collaboration and communication can be nurtured and enhanced when working with new management and cross functional teams in a new leadership role. A new didactic and lecture style approach is sure to keep stewards engaged while providing well prepared feedback on how to effectively communicate with hospital leadership.
As the faculty or stewardship champion leading this effort, you can decide how the content is distributed and presented to your stewards- in- training.
For Stewards - in - Training:
The fellow/trainee can watch the eLearning on their own, followed by a debrief between fellow and faculty.
To present in a classroom or small group setting, you can open the eLearning and let it talk for you, controlling the slides and the pace. You can also disable the audio and narrate the eLearning yourself.
Program Directors, Antimicrobial Stewardship Faculty Champions, and additional Faculty responsible for leading and implementing the Curriculum.
Upon completion of this section, stewards- in- training will be able to:
- Employ effective techniques to deal with the “outlier” prescriber, non-formulary requests, special populations
- Recognize programmatic approaches to effective AS communication (including initiatives to involve nursing staff)
- Describe the steps involved in promoting culture change in institutions
- Demonstrate communication skills to negotiate with hospital leadership
- Explain the behavioral psychology of clinicians regarding antimicrobial use
- Explain the behavioral psychology of patients regarding antimicrobial use
- Propose effective techniques to change antimicrobial prescribing habits of others
- Adopt communication skills to influence the prescribing habits of others
AS Curriculum Workgroup COI Summary Reviewed April 2017 by Rachel Simmons, MD No conflicts found
|Name||Individual's Role in Activity||Name of Commercial Interest||Nature of Relationship|
|Abbo, Lillian||Workgroup member||Pfizer Brazil||Honoraria|
|Advani, Sonali||Workgroup member||Nabriva Therapeutics||Advisory/Consultant Role|
|Amstrong, Wendy||Workgroup member||None|
|Barsoumian, Alice||Workgroup member||None|
|Beeler, Cole||Workgroup member||None|
|Bystritsky, Rachel||Workgroup member||None|
|Cherabuddi, Kartik||Workgroup member||Gatorade||Start - up Research Fund|
|NIH (Medimmune)||Research Grant|
|Cohen, Seth||Workgroup member||None|
|Hamilton, Keith||Workgroup member||None|
|Ince, Dilek||Workgroup member||Ansun Pharma||Research Grant|
|Justo, Julie Ann||Workgroup member||None|
|Luther, Vera||Workgroup member||None|
|Lynch, John||Workgroup member||Astellas Pharmaceuticals, Juno Therapeutics||Advisory/Consultant Role|
|Nori, Priya||Workgroup member||None|
|Ohl, Christopher||Workgroup member||Paratek, Bayer, Cempra Pharmaceuticals||Advisory/Consultant Role|
|Patel, Payal||Workgroup member||None|
|Pottinger, Paul||Workgroup member||McGraw Hill, Elsevier||Honoraria|
|Schwartz, Brian||Workgroup member||None|
|Spicer, Jennifer||Workgroup member||None|
|Stack, Conor||Workgroup member||None|
|Zhou, Yuan||Workgroup member||None|